ArticleJournal of cachexia, sarcopenia and muscle2016
ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.
Article in Journal of cachexia, sarcopenia and muscle, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Review
- Role of diet, physical activity and new drugs in the primary management of cancer cachexia in gastrointestinal tumors - a comprehensive review.Frontiers in oncology · 2025Review
- Review
- Unraveling the lost balance: Adrenergic dysfunction in cancer cachexia.Autonomic neuroscience : basic & clinical · 2024Review
- Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management.Nature reviews. Clinical oncology · 2023Review
- Nutritional and Exercise Interventions in Cancer-Related Cachexia: An Extensive Narrative Review.International journal of environmental research and public health · 2022Review
- Cancer Cachexia and Related Metabolic Dysfunction.International journal of molecular sciences · 2020Review
- Cancer cachexia: an orphan with a future.Journal of cachexia, sarcopenia and muscle · 2019Article
- Therapeutic strategies against cancer cachexia.European journal of translational myology · 2019Article
- Is Neuronal Histamine Signaling Involved in Cancer Cachexia? Implications and Perspectives.Frontiers in oncology · 2019Article
- Contemporary publication patterns in the Journal of Cachexia, Sarcopenia and Muscle by type and sub-speciality: facts and numbers.Journal of cachexia, sarcopenia and muscle · 2018Article
- Metabolic disorders in heart failure and cancer.ESC heart failure · 2018Review
- Skeletal muscle wasting in chronic heart failure.ESC heart failure · 2018Review
- Time to jump on the bandwagon: the Journal of Cachexia, Sarcopenia and Muscle in 2018.Journal of cachexia, sarcopenia and muscle · 2018Article
- Article
- Casting the net broader to confirm our imaginations: the long road to treating wasting disorders.Journal of cachexia, sarcopenia and muscle · 2017Article
- Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).ESC heart failure · 2017Article
- Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017.Journal of cachexia, sarcopenia and muscle · 2017Article
- ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.Journal of cachexia, sarcopenia and muscle · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel action beta-blockers combine many different pharmacological effects. The espindolol exhibits effects through β and central 5-HT1α receptors to demonstrate pro-anabolic, anti-catabolic, and appetite-stimulating actions. In the ACT-ONE trial, espindolol reversed weight loss and improved handgrip strength in patients with cachexia due to non-small cell lung cancer or colorectal cancer. With this trial, another frontier of cachexia management is in sight. Nonetheless, more efficacy and safety data is needed before new therapeutic indications for novel action beta-blockers can be endorsed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.